|Application ||WB, IF, E|
|Calculated MW||59348 Da|
|Antigen Region||407-435 aa|
|Other Names||Cytochrome P450 4A11, 20-hydroxyeicosatetraenoic acid synthase, 20-HETE synthase, CYP4AII, CYPIVA11, Cytochrome P-450HK-omega, Cytochrome P450HL-omega, Fatty acid omega-hydroxylase, Lauric acid omega-hydroxylase, CYP4A11, CYP4A2|
|Target/Specificity||This CYP4A11 (4A22) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 407-435 amino acids from the C-terminal region of human CYP4A11 (4A22).|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||CYP4A11 (4A22) Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate, myristate and palmitate. Has little activity toward prostaglandins A1 and E1. Oxidizes arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE).|
|Cellular Location||Endoplasmic reticulum membrane; Peripheral membrane protein. Microsome membrane; Peripheral membrane protein|
|Tissue Location||Kidney and liver.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CYP4A11 is a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and hydroxylates medium-chain fatty acids such as laurate and myristate.
Sugimoto,K., Hypertension 52 (6), 1142-1148 (2008)
Ward,N.C., Hypertension 51 (5), 1393-1398 (2008)
Nelson,D.R., Pharmacogenetics 14 (1), 1-18 (2004)
If you have any additional inquiries please email technical services at email@example.com.